{"ticker": {"uuid": "1a99e02c-8452-4827-a2f2-f2d86b6c6b7f", "symbol": "NEU", "name": "Neuren Pharmaceuticals Limited", "exchange": "ASX", "country": "AU", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Growth Investors: Industry Analysts Just Upgraded Their Neuren Pharmaceuticals Limited (ASX:NEU) Revenue Forecasts By 55%", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-06T07:00:00+00:00", "published_display": "06 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neuren Pharmaceuticals (ASX:NEU) Draws Investor Attention After Recent Decline", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxNY1NxR3B2STRIZklSazJINEMzSEotUUJzczd4em1ENzN3Rm5vUWdWMzQyYkVXTzI4VGtTd1kyT00tN2Nub0NvQTZaRDdXMm5weUUxNUlHZkR5YzNvVjdGOFltdDFGZDNLWFZncnYtSktUR19lcWJaOHU1Q0Y1OUExZ184LXluN1hGYm1yb3Mzd2JzWmNPTjRGVnk3SnFxX1MzclA2OElYUDdhZ252V01GZm4ya3I?oc=5", "source_name": "Kalkine", "published_at": "2026-07-03T07:00:00+00:00", "published_display": "03 Jul 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neuren Pharmaceuticals (ASX:NEU): Biotech Momentum Builds as This ASX Healthcare Stock Rises Again", "summary": "", "url": "https://news.google.com/rss/articles/CBMizgFBVV95cUxPWDluQVdfY0k1NmVaa3cyVEh4WThQNGlRUG9hTXNDcXRmNmYzOFZfVno2RklmSmNaYW9SRlItdTgwdnA5SGgzXzFjQ3k5SFZVWWxPSGU2cTlBSTRiRG9aYXpPYnZaSnpqVFdFUkJUZXQyazZ5YjBaVFFOVU9kMzl2RnF5cGM3cGhtdDU4UmliZDJqbmtDcUFaSk9YMVk0azY2d0ZNOVdnTHFmWEJmak9qMEpZdFliQktUM0NMbXdOa3hDWnEyV3ZyX2tCRjhBQQ?oc=5", "source_name": "Kalkine", "published_at": "2026-07-01T07:00:00+00:00", "published_display": "01 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neuren Pharmaceuticals (ASX:NEU) Draws Attention as Drug Pipeline Strengthens", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxPQTdkYnNqdXk0WHY0Q0RIUnlpWl9wWFM3OGNwRzlsR0p6RExhUk90YjVIVzcxUWZEakZRQkpzV2NlVE05dV9tZUFDTjNiRno3Qy1Wdk9DN3M4SDdvclVITUJqVFlhdURXeW5NSVBWVWpsRGZGWUFJQVU3UVlaNm5rejVfdWlXSGhINE5sNGRIcUh1NVlzNmtyN3FzSEtUTkJWYXR6M3JQWV9ZMGdheHdSR1puR1hna3kzRll4Vg?oc=5", "source_name": "Kalkine Media", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neuren Pharmaceuticals (ASX:NEU): Biotech Growth Stock Returns to Market Conversation", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxPZC16S2FtRExaanhVc2ROalZhdzYweWYyVE03QzVTYUlNZTVYUjB2RzVHRS1NQjRGS0p2bXViaTY0SjdWTUU2QlpMNExIU3o1aGNLd2JnQkpyWWpXQkM3VDBiWWdkMW44Mk83S2lPMUZYMDJMMHZUZnZ2Q0czdTVCMmF4WjA5bThfZjJDUDNrVnZUeXh4MFEwaFNLclJERUZ6Tmp6QmFPZjNaTV9fcnIxV3VQZ0ZuMHdyeU9OUw?oc=5", "source_name": "Kalkine", "published_at": "2026-06-19T07:00:00+00:00", "published_display": "19 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neuren Pharmaceuticals (ASX:NEU) Gains Momentum as Investors Track Pipeline and Commercial Progress", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0AFBVV95cUxNc2hVM1NrU3dCYTI2RU5sUFVod1NEV0xESXNoOWFrY2VhVWZDdGhicjVJR3FJMFItNk1majVtM2tNZHk5TGZScVpjVFRvU0hjbkpTSmdEYVE3ak9XdWhOaGZUYkxWdkZuamZwUlJja1ZLb1VXSGt3X2NxYzlMOUhsWFdoRVZNOVZqUVdEVFUybWR2UHJyaTBMWWdWc2FTRHlXZW1CaXBkdnJBNHlNU1JDTndTTW1YTUJxLUpMU3FrSWxhY0p0cjl0MTlnT2ZQNDNn?oc=5", "source_name": "Kalkine", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neuren Pharmaceuticals Issues 450,000 New Shares After Employee Options Exercised at $3.83", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxNbzRLZm5oN3hNNTR3MmwtMDZBX1hQNi1HbFF5blR6WmFrR05ibElxZGFCcGRPTWxLWnBVd0pDWEZBanp6NGVxVUNINlVZMXlOQ0tfVWktNUMwZUpVVnBabFI1QjlnXzNhMGNaTFhkckphQmhvc0hUbGZJZXNSeUhMZ2k2NFp5bEtxZmx1SUl2TTh4LVZoZlU0YVJ3ejRObkF2U21UYnVYVEJyeFB5ZWFTd1N2ZG5VN091NGtyc09WYThNNG9QR0FLZQ?oc=5", "source_name": "Kalkine", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Neuren (ASX:NEU) Stock Worth Watching After Its Latest DAYBUE Update?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxNZzY1aWFtbzA5VGdNNzhmTHVGUVVfNEhqcHRpZTVESTVUNmhMSkRUcE83cVhlbHpYcnF0V1o5bllVREdPaGdpdDV2Y1hkekd0a1AtV0RCMzZPUlRrcXl0eVc4dnp2N09QeHh2cW93b29hVUFqQ0txM1VqY204azFxV0lmTmVQZzRWMVZiakdOTkNyOVA2SXB6SXRLamhqOUxzQ2l3SXNQV0ZEUmM?oc=5", "source_name": "Kalkine", "published_at": "2026-05-27T07:00:00+00:00", "published_display": "27 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Neuren Pharmaceuticals (ASX:NEU) Is Up 6.3% After Record DAYBUE Royalties And Strong STIX Launch \u2013 And What's Next", "summary": "", "url": "https://news.google.com/rss/articles/CBMi8AFBVV95cUxOM2dVZVhNUDJYdEdfVzY3dDJzUzAyNkd1X2ZWRkpJVFAwQkhGRExnUElvZ0FpTEl3X3V1STlFWjNnZ1NFVlRoaE5RMTUwb01tdThicFNYWlBUS0E2dGx4T1NqSWtTTHdGbUx2dmxDWmIzalhlZVJ4YTdsSEU0NEl1d3dxU0FMLWc5Zi12Q2VkU0NoSVplNGFCSWY4QUllU3VUd3N1eFpKQVNMMGJfOFFCUHZEUFRiaVdTN2JQYjlRNncxazZIRUwtY1Jpd2RldWZlczZ6ckMwSlpmSFZ4RTNMNFZYQVFfejViUFdhcmRRMGrSAfYBQVVfeXFMT2lCQjI2cFNzTnZiUDZ5a1JJTUZZRVc4aDVYcER5d1N1X1JZYTczYTh1Y0RJTGNRT3Y5NDlGMWFaRm92dkhKTWlCNm9oY0N4Wk9oeDB3ckdLc0xEVGgxT3N2aVp3UnJDRVJjV0EyaG95X2VrWEJnNzA5aU5FanJ1a09XUVVmbDlqMnlpWWk1Z0pyUk1vRTgzVk05OVRmRG9TeTJEVUxTSGlERVpuc0tQRHBHa29WUzJtT3RfUlZiTU1lMXQ4N0YyQUZtcXNqYnpUZWZLVklxVzlHRWJrRzNFMk1SUk5VbGxoLVN4NEhMc2ViS05KODZB?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neuren Pharmaceuticals Q1 2026: DAYBUE sales soar", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxPWFlLSUJQYU5OQTNxV0MwVUlJREI4RlZmNno2a0J0el9DbUotanpvVkIwMHFQc2JjMFZYSzRlVmtOT2h3QWUxdko4NkdYcS1EQ3JSSnhNR0ZBZ2Zfb2ExOXNpSVFCX3Q4cWhYeUFydlJOUDZXajNWcEpCSXlrRkxFLUZKT0hOTzByc3MtVw?oc=5", "source_name": "The Motley Fool Australia", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Neuren shares are rebounding on Wednesday after a brutal 2026 sell-off", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxNSUxtOXUyM2tJS05SYU90ZW9UazJOSUxiaTJrd2JzNUJsUWNRQ05tb1FXMDZlOUl3Qkh1c2NjOWFtSTdpSk1NUkZhOEx1a3g3OHVvaXoxelRmcVZOdGdNWmZQd3V3OVdHMG1DQXNHOU5lUVRUb0poS1hZOTB5b2sxT29mbzY1WGRMa1VST2ZaRFFMZzJadzg2eDlnNnJVaC15NWVTT3U5M3lXNlpjcGdr?oc=5", "source_name": "The Motley Fool Australia", "published_at": "2026-04-08T07:00:00+00:00", "published_display": "08 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neuren Pharmaceuticals FY 2025 Margin Strength Tests Earnings Quality Concerns", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-02-28T08:00:00+00:00", "published_display": "28 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Even though Neuren Pharmaceuticals (ASX:NEU) has lost AU$528m market cap in last 7 days, shareholders are still up 779% over 5 years", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxPM2dZN094ME15bk1HQ3NVVkVZamtaTGNUVnVnZUJvT1BrZFVrNWFucFg0OHkzclBBUklXLVE4bHFNc1hRaTFYbzROSnBVeVRFRmxwd0M4RXdicjNEbTZMa2dNYVIzaFNYMmU5NUdqLVNGUUlpSHFiZjk2R3M1ZVNmaFNSS2s3NVVHMDItVg?oc=5", "source_name": "Market source", "published_at": "2026-02-08T08:00:00+00:00", "published_display": "08 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Slammed 30% Neuren Pharmaceuticals Limited (ASX:NEU) Screens Well Here But There Might Be A Catch", "summary": "", "url": "https://news.google.com/rss/articles/CBMi8AFBVV95cUxQVGw4a3hEVmNzYXhZdFl6VWtnU3ZwTXI5TThGV2l2LVNvNDA3dm5WYzRHT0w2VUMzNnlfMWl2YmtWUTFaMjYzMTV0YktQV3p0OFdBZ3JfWGRfUDVqbW9VdmhWajNWQ1lNQjhDVzVIMTFfSkRKWDhrTzBQUEpOdHgyWEdJczlPY1IzMm5qelo4QUxRelE1MkliV3BhcVNQZ3NIc0hka01XdEpVTTNacnBvaDRabjRXNGNuWjFwaEZodWZsb2ZqY1pEeUFGcUI2SkxaQzJYN2RvLWdkeU1PSkV5RkhvR1R0SEI3bEZpUDV2RW_SAfYBQVVfeXFMTXZCZHJ3cHlfUjEyeHgyUHRGeHpwV0QzeHJ4SUxOTC1yOEFVZF9GaWVtd0E1UDJtVkdhWWhqeEtnbVo0T19GUkpPSzFVWllrWDFMT3NCYjlVVkFCRWE0RFEwaDBNQks0TFRhWHpSaGRETEJpSHJJU21jZzcyVEhFOURxalBFVHpKV1E2bkpvNGtmVzdxc2lHekV2bkoxdlFEZDhDeXBDWUFscHV5Nmt6enl3MEdLQWo2M3paeGZtdG9zbjZ3dmVhZjRmcTkwSk9xMjZ1WVlMTUlzR2tUUXdxWXBWa0pmSXBGTjFuek5NTThsRDhKS1Zn?oc=5", "source_name": "simplywall.st", "published_at": "2026-02-05T08:00:00+00:00", "published_display": "05 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inside Biotech: Neuren\u2019s tough week highlights biotech\u2019s regulatory fault lines", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxQNnRTZk1rLWt0eUkzSGdZc0V4VE8wZTRYb21ZY0R0QmJ3dmFTMDE3ZjZmVVJSS00tU0dTXzZjTVpmSWFGekJSdkx6bTVKMEFyRElOdjV4b0dLazJLeEhvYWdwQ2lTeER1SGhHaV9aV3RKWUhiRE1rM2xad1JlSVhUcGJoV3NkOE9R?oc=5", "source_name": "Market source", "published_at": "2026-02-03T08:00:00+00:00", "published_display": "03 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neuren Pharmaceuticals Shares Extend Slide on European Setback", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxQdUZTUFhSSkxFcTJjbUVrS0VuYnplQXB2N2FLNkttLU96a3MxNEJ5dHctQ3AxV2JwN1RKcm9PRnhMY24zZ3pCMkdwejRNVS1EUS1xU2UtajBOWmJRWF93eXhhdmJZbUtHb0Ytdjl0azA0ek9xZDA2VFRxdVNRYnlsT0Y5d0FZVUVHWWJPam9PemdzZkVISnc?oc=5", "source_name": "thebull.com.au", "published_at": "2026-02-03T08:00:00+00:00", "published_display": "03 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neuren Pharmaceuticals revises DAYBUE revenue projections to reach US$700 million in 2028", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxONlNPelVpOVRVdE1INnpoWl92N05qZWZyMjg4TmNpX20zeElQbW91ZGZQUnpSS1pXMFpXYmZJVm1nalJEM1FnMDN4ZDdudnFjUkI2aV9mWWRQS1pMdmlWc1N5Vnhmb2dkNGVscWxteTlkTzZnY1l5ZnMtb19DcFFFZTFiUUh0dlpjbEYzcW0yb2RtVnN5WGpucDBoZ3dGZExSR1FZT3UyWTJwS0owNFppZXQzZzdaa2twSXlvRXgxdjBMUQ?oc=5", "source_name": "The Motley Fool Australia", "published_at": "2026-01-19T08:00:00+00:00", "published_display": "19 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Australian Shares Flat; Neuren Pharmaceuticals' Nasdaq-Listed Partner Forecasts Rett Syndrome Drug Global Net Sales to Reach $700 Million in 2028", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxQZkRaM1BkbFhQTUZWdExXV1BzUlVqY2I5OWZkeUI0T3pCV2RBOEd2VkNTM01CMDRfb3NFYjZPY2tMVVF4SUg1RW9kOEoxNjdhQVdvenFMeXlkb21ickxUNmxydzZSVE5BUlM2YkNvMkttdWlyR2ZkNUdRWExSdng5ZzFETEUyWXdoeW03djJ0WFFGZGdULVJLS0xn?oc=5", "source_name": "Market source", "published_at": "2026-01-13T08:00:00+00:00", "published_display": "13 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Investors Shouldn't Be Too Comfortable With Neuren Pharmaceuticals' (ASX:NEU) Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-09-02T07:00:00+00:00", "published_display": "02 Sep 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why We Think Neuren Pharmaceuticals (ASX:NEU) Is Well Worth Watching", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-08-27T07:00:00+00:00", "published_display": "27 Aug 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Growth Investors: Industry Analysts Just Upgraded Their Neuren Pharmaceuticals Limited (ASX:NEU) Revenue Forecasts By 55%", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-06T07:00:00+00:00", "published_display": "06 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neuren Pharmaceuticals (ASX:NEU) Draws Investor Attention After Recent Decline", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxNY1NxR3B2STRIZklSazJINEMzSEotUUJzczd4em1ENzN3Rm5vUWdWMzQyYkVXTzI4VGtTd1kyT00tN2Nub0NvQTZaRDdXMm5weUUxNUlHZkR5YzNvVjdGOFltdDFGZDNLWFZncnYtSktUR19lcWJaOHU1Q0Y1OUExZ184LXluN1hGYm1yb3Mzd2JzWmNPTjRGVnk3SnFxX1MzclA2OElYUDdhZ252V01GZm4ya3I?oc=5", "source_name": "Kalkine", "published_at": "2026-07-03T07:00:00+00:00", "published_display": "03 Jul 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neuren Pharmaceuticals (ASX:NEU): Biotech Momentum Builds as This ASX Healthcare Stock Rises Again", "summary": "", "url": "https://news.google.com/rss/articles/CBMizgFBVV95cUxPWDluQVdfY0k1NmVaa3cyVEh4WThQNGlRUG9hTXNDcXRmNmYzOFZfVno2RklmSmNaYW9SRlItdTgwdnA5SGgzXzFjQ3k5SFZVWWxPSGU2cTlBSTRiRG9aYXpPYnZaSnpqVFdFUkJUZXQyazZ5YjBaVFFOVU9kMzl2RnF5cGM3cGhtdDU4UmliZDJqbmtDcUFaSk9YMVk0azY2d0ZNOVdnTHFmWEJmak9qMEpZdFliQktUM0NMbXdOa3hDWnEyV3ZyX2tCRjhBQQ?oc=5", "source_name": "Kalkine", "published_at": "2026-07-01T07:00:00+00:00", "published_display": "01 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neuren Pharmaceuticals (ASX:NEU) Draws Attention as Drug Pipeline Strengthens", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxPQTdkYnNqdXk0WHY0Q0RIUnlpWl9wWFM3OGNwRzlsR0p6RExhUk90YjVIVzcxUWZEakZRQkpzV2NlVE05dV9tZUFDTjNiRno3Qy1Wdk9DN3M4SDdvclVITUJqVFlhdURXeW5NSVBWVWpsRGZGWUFJQVU3UVlaNm5rejVfdWlXSGhINE5sNGRIcUh1NVlzNmtyN3FzSEtUTkJWYXR6M3JQWV9ZMGdheHdSR1puR1hna3kzRll4Vg?oc=5", "source_name": "Kalkine Media", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neuren Pharmaceuticals (ASX:NEU): Biotech Growth Stock Returns to Market Conversation", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxPZC16S2FtRExaanhVc2ROalZhdzYweWYyVE03QzVTYUlNZTVYUjB2RzVHRS1NQjRGS0p2bXViaTY0SjdWTUU2QlpMNExIU3o1aGNLd2JnQkpyWWpXQkM3VDBiWWdkMW44Mk83S2lPMUZYMDJMMHZUZnZ2Q0czdTVCMmF4WjA5bThfZjJDUDNrVnZUeXh4MFEwaFNLclJERUZ6Tmp6QmFPZjNaTV9fcnIxV3VQZ0ZuMHdyeU9OUw?oc=5", "source_name": "Kalkine", "published_at": "2026-06-19T07:00:00+00:00", "published_display": "19 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neuren Pharmaceuticals (ASX:NEU) Gains Momentum as Investors Track Pipeline and Commercial Progress", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0AFBVV95cUxNc2hVM1NrU3dCYTI2RU5sUFVod1NEV0xESXNoOWFrY2VhVWZDdGhicjVJR3FJMFItNk1majVtM2tNZHk5TGZScVpjVFRvU0hjbkpTSmdEYVE3ak9XdWhOaGZUYkxWdkZuamZwUlJja1ZLb1VXSGt3X2NxYzlMOUhsWFdoRVZNOVZqUVdEVFUybWR2UHJyaTBMWWdWc2FTRHlXZW1CaXBkdnJBNHlNU1JDTndTTW1YTUJxLUpMU3FrSWxhY0p0cjl0MTlnT2ZQNDNn?oc=5", "source_name": "Kalkine", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neuren Pharmaceuticals Issues 450,000 New Shares After Employee Options Exercised at $3.83", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxNbzRLZm5oN3hNNTR3MmwtMDZBX1hQNi1HbFF5blR6WmFrR05ibElxZGFCcGRPTWxLWnBVd0pDWEZBanp6NGVxVUNINlVZMXlOQ0tfVWktNUMwZUpVVnBabFI1QjlnXzNhMGNaTFhkckphQmhvc0hUbGZJZXNSeUhMZ2k2NFp5bEtxZmx1SUl2TTh4LVZoZlU0YVJ3ejRObkF2U21UYnVYVEJyeFB5ZWFTd1N2ZG5VN091NGtyc09WYThNNG9QR0FLZQ?oc=5", "source_name": "Kalkine", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Neuren (ASX:NEU) Stock Worth Watching After Its Latest DAYBUE Update?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxNZzY1aWFtbzA5VGdNNzhmTHVGUVVfNEhqcHRpZTVESTVUNmhMSkRUcE83cVhlbHpYcnF0V1o5bllVREdPaGdpdDV2Y1hkekd0a1AtV0RCMzZPUlRrcXl0eVc4dnp2N09QeHh2cW93b29hVUFqQ0txM1VqY204azFxV0lmTmVQZzRWMVZiakdOTkNyOVA2SXB6SXRLamhqOUxzQ2l3SXNQV0ZEUmM?oc=5", "source_name": "Kalkine", "published_at": "2026-05-27T07:00:00+00:00", "published_display": "27 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Neuren Pharmaceuticals (ASX:NEU) Is Up 6.3% After Record DAYBUE Royalties And Strong STIX Launch \u2013 And What's Next", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neuren Pharmaceuticals Q1 2026: DAYBUE sales soar", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxPWFlLSUJQYU5OQTNxV0MwVUlJREI4RlZmNno2a0J0el9DbUotanpvVkIwMHFQc2JjMFZYSzRlVmtOT2h3QWUxdko4NkdYcS1EQ3JSSnhNR0ZBZ2Zfb2ExOXNpSVFCX3Q4cWhYeUFydlJOUDZXajNWcEpCSXlrRkxFLUZKT0hOTzByc3MtVw?oc=5", "source_name": "The Motley Fool Australia", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Neuren shares are rebounding on Wednesday after a brutal 2026 sell-off", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxNSUxtOXUyM2tJS05SYU90ZW9UazJOSUxiaTJrd2JzNUJsUWNRQ05tb1FXMDZlOUl3Qkh1c2NjOWFtSTdpSk1NUkZhOEx1a3g3OHVvaXoxelRmcVZOdGdNWmZQd3V3OVdHMG1DQXNHOU5lUVRUb0poS1hZOTB5b2sxT29mbzY1WGRMa1VST2ZaRFFMZzJadzg2eDlnNnJVaC15NWVTT3U5M3lXNlpjcGdr?oc=5", "source_name": "The Motley Fool Australia", "published_at": "2026-04-08T07:00:00+00:00", "published_display": "08 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neuren Pharmaceuticals FY 2025 Margin Strength Tests Earnings Quality Concerns", "summary": "", "url": "https://news.google.com/rss/articles/CBMi8AFBVV95cUxQcjh2NVl6Qy1yV0xsdzFTQ3JyUjdpMUpURWNRVzl0ZTVlb25Ha1F5RzhZVHZBX09zbXFUSDhwMDhZWi1VY1BXUi1WYmxJY29STExQV3ZWaENWeWMwVDdXWnEtbERBYnVUcmFIUEhDV0luSkFOeF9ia1VsRGplNHl0N0NhYXVCR1lzV05fRTFPZXFTSl9wQXFNbEVPOVk5SVFVQ1Z2b19mZjhSdVlEdDNObE5kcE52T1U5b25NQjN1clZVTVlTbGMxRlRWNkpUdTQyM3RfRkZNTGs5alJILTQxaExobFdETzc1TDdUWk9PX2zSAfYBQVVfeXFMTWVZTFR6QTFiaDlpTEJrRzcxWGxjLXExcmFsMkxZOHB3ZmNEWVVqMkVWNzVQbUdacnlrUF9pODZ0V3kxWHVoRTZsUUJPSGdtbW1aUzBrTUJEa2U0bktMcWZhWjZpNDFvOWY2RUJlTWJHekI2aWtPTXMtQkp2bGRaRU1PNkRDazQ0enNnLW1acXp2akd0QklBSTg3dlhSRkpWWlJiUGozSHJ1YlZ4a0R3Rk5GdHMyNGlDVWczS3hLcjM2Tkl1ODhyb0llWTliRE1YYWpWZlRYVGwySHhiZE1fWWZzS0FjdVFaMjVsRU5la2JGRTNKZnhR?oc=5", "source_name": "simplywall.st", "published_at": "2026-02-28T08:00:00+00:00", "published_display": "28 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Even though Neuren Pharmaceuticals (ASX:NEU) has lost AU$528m market cap in last 7 days, shareholders are still up 779% over 5 years", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxPM2dZN094ME15bk1HQ3NVVkVZamtaTGNUVnVnZUJvT1BrZFVrNWFucFg0OHkzclBBUklXLVE4bHFNc1hRaTFYbzROSnBVeVRFRmxwd0M4RXdicjNEbTZMa2dNYVIzaFNYMmU5NUdqLVNGUUlpSHFiZjk2R3M1ZVNmaFNSS2s3NVVHMDItVg?oc=5", "source_name": "Market source", "published_at": "2026-02-08T08:00:00+00:00", "published_display": "08 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Slammed 30% Neuren Pharmaceuticals Limited (ASX:NEU) Screens Well Here But There Might Be A Catch", "summary": "", "url": "https://news.google.com/rss/articles/CBMi8AFBVV95cUxQVGw4a3hEVmNzYXhZdFl6VWtnU3ZwTXI5TThGV2l2LVNvNDA3dm5WYzRHT0w2VUMzNnlfMWl2YmtWUTFaMjYzMTV0YktQV3p0OFdBZ3JfWGRfUDVqbW9VdmhWajNWQ1lNQjhDVzVIMTFfSkRKWDhrTzBQUEpOdHgyWEdJczlPY1IzMm5qelo4QUxRelE1MkliV3BhcVNQZ3NIc0hka01XdEpVTTNacnBvaDRabjRXNGNuWjFwaEZodWZsb2ZqY1pEeUFGcUI2SkxaQzJYN2RvLWdkeU1PSkV5RkhvR1R0SEI3bEZpUDV2RW_SAfYBQVVfeXFMTXZCZHJ3cHlfUjEyeHgyUHRGeHpwV0QzeHJ4SUxOTC1yOEFVZF9GaWVtd0E1UDJtVkdhWWhqeEtnbVo0T19GUkpPSzFVWllrWDFMT3NCYjlVVkFCRWE0RFEwaDBNQks0TFRhWHpSaGRETEJpSHJJU21jZzcyVEhFOURxalBFVHpKV1E2bkpvNGtmVzdxc2lHekV2bkoxdlFEZDhDeXBDWUFscHV5Nmt6enl3MEdLQWo2M3paeGZtdG9zbjZ3dmVhZjRmcTkwSk9xMjZ1WVlMTUlzR2tUUXdxWXBWa0pmSXBGTjFuek5NTThsRDhKS1Zn?oc=5", "source_name": "simplywall.st", "published_at": "2026-02-05T08:00:00+00:00", "published_display": "05 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inside Biotech: Neuren\u2019s tough week highlights biotech\u2019s regulatory fault lines", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxQNnRTZk1rLWt0eUkzSGdZc0V4VE8wZTRYb21ZY0R0QmJ3dmFTMDE3ZjZmVVJSS00tU0dTXzZjTVpmSWFGekJSdkx6bTVKMEFyRElOdjV4b0dLazJLeEhvYWdwQ2lTeER1SGhHaV9aV3RKWUhiRE1rM2xad1JlSVhUcGJoV3NkOE9R?oc=5", "source_name": "Market source", "published_at": "2026-02-03T08:00:00+00:00", "published_display": "03 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neuren Pharmaceuticals Shares Extend Slide on European Setback", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxQdUZTUFhSSkxFcTJjbUVrS0VuYnplQXB2N2FLNkttLU96a3MxNEJ5dHctQ3AxV2JwN1RKcm9PRnhMY24zZ3pCMkdwejRNVS1EUS1xU2UtajBOWmJRWF93eXhhdmJZbUtHb0Ytdjl0azA0ek9xZDA2VFRxdVNRYnlsT0Y5d0FZVUVHWWJPam9PemdzZkVISnc?oc=5", "source_name": "thebull.com.au", "published_at": "2026-02-03T08:00:00+00:00", "published_display": "03 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neuren Pharmaceuticals revises DAYBUE revenue projections to reach US$700 million in 2028", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxONlNPelVpOVRVdE1INnpoWl92N05qZWZyMjg4TmNpX20zeElQbW91ZGZQUnpSS1pXMFpXYmZJVm1nalJEM1FnMDN4ZDdudnFjUkI2aV9mWWRQS1pMdmlWc1N5Vnhmb2dkNGVscWxteTlkTzZnY1l5ZnMtb19DcFFFZTFiUUh0dlpjbEYzcW0yb2RtVnN5WGpucDBoZ3dGZExSR1FZT3UyWTJwS0owNFppZXQzZzdaa2twSXlvRXgxdjBMUQ?oc=5", "source_name": "The Motley Fool Australia", "published_at": "2026-01-19T08:00:00+00:00", "published_display": "19 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Australian Shares Flat; Neuren Pharmaceuticals' Nasdaq-Listed Partner Forecasts Rett Syndrome Drug Global Net Sales to Reach $700 Million in 2028", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxQZkRaM1BkbFhQTUZWdExXV1BzUlVqY2I5OWZkeUI0T3pCV2RBOEd2VkNTM01CMDRfb3NFYjZPY2tMVVF4SUg1RW9kOEoxNjdhQVdvenFMeXlkb21ickxUNmxydzZSVE5BUlM2YkNvMkttdWlyR2ZkNUdRWExSdng5ZzFETEUyWXdoeW03djJ0WFFGZGdULVJLS0xn?oc=5", "source_name": "Market source", "published_at": "2026-01-13T08:00:00+00:00", "published_display": "13 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Investors Shouldn't Be Too Comfortable With Neuren Pharmaceuticals' (ASX:NEU) Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-09-02T07:00:00+00:00", "published_display": "02 Sep 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why We Think Neuren Pharmaceuticals (ASX:NEU) Is Well Worth Watching", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-08-27T07:00:00+00:00", "published_display": "27 Aug 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 89, "total_relevant": 20, "sentiment_summary": {"positive": 4, "negative": 1, "neutral": 15, "score": 53, "total": 20, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 86, "events": [{"event": "general", "label": "Market update", "weight": 8.25, "count": 15}, {"event": "earnings", "label": "Earnings", "weight": 2.2, "count": 4}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 0.55, "count": 1}], "positive_events": 4, "negative_events": 1}, "market_context": {"has_market_context": true, "latest_close": 16.52, "latest_week": "2026-07-10", "one_week_move": -1.3, "four_week_move": 23.4, "twelve_week_move": 32.3, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 1.108949, "market_dynamics_buy_signal": false, "relative_strength": 0.946062, "fair_value_gap": 4.2, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "undecided", "expectation_probability": 48.6615, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "-1.3% over one week, +23.4% over four weeks, trend inactive, and near fair-value range."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 64, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "simplywall.st", "count": 6}, {"label": "Kalkine", "count": 6}, {"label": "The Motley Fool Australia", "count": 3}, {"label": "Market source", "count": 3}, {"label": "Kalkine Media", "count": 1}, {"label": "thebull.com.au", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 20}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 15}, {"label": "Earnings", "count": 4}, {"label": "Regulatory and legal", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "53/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "86/100 classification confidence."}, {"label": "Company focus", "value": "20", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-1.3% over one week, +23.4% over four weeks, trend inactive, and near fair-value range."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Growth Investors: Industry Analysts Just Upgraded Their Neuren Pharmaceuticals Limited (ASX:NEU) Revenue Forecasts By 55%"}], "updated_at": "2026-07-17T06:17:27.089924+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}